Could PF-06480605 Phase IIb trial registration pave the way for Pfizer’s dominance in UC space?
Pfizer’s PF-06480605 is an antibody that blocks tumour necrosis factor.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
